Five Reasons You Should No Longer Bother Getting U.S. Patents

By Dennis Fernandez, Esq.,
Fernandez & Associates, LLP. 

Feb. 4, 2008 | In light of recent court decisions and proposed policy changes affecting U.S. patent law, U.S. patents may no longer provide patentees with the worthwhile protection originally afforded to inventors under the legal system as an incentive and in exchange for time and resources invested in innovation.

1.   There is no longer any guarantee of exclusive patent protection. 
 
According to the U.S. Supreme Court in the recent eBay v. MercExchange case (involving eBay's infringement of MercExchange's patented technologies for both online auctions and a direct-buy system), there is no longer any assurance that rightful owners of valid U.S. patents have any legal right to prevent unlawful trespassers from infringing their patents.  In particular, the eBay case specifically held that mere patent owners (e.g. non-practicing inventors or university researchers) cannot automatically assume they have any legal power to litigate against proven infringers to seek injunctive relief to block unlawful trespass.
 
2.   There is no longer current assurance of reliable patent licensing.
 
Recently, again according to the U.S. Supreme Court in the MedImmune v. Genentech case (in which MedImmune, a licensee of a drug patent owned by Genentech, was able to bring a declaratory judgment action challenging Genentech's patent without exposing itself to liability by breaching the license agreement), a patent owner who licenses his or her patents via legally-binding patent license agreements can no longer prevent the licensees of these valid patent license agreements from then suing the patent owner to challenge the validity of the patents; and in the meantime, these licensees can still receive the benefit of the licensed patent rights.
 
3.  An inventor cannot seek patent protection for "merely a combination of old elements."
 
And, more recently, according to the U.S. Supreme Court in the KSR International v. Teleflex case (in which the court overturned a 24-year precedent and held that Teleflex's gas pedal patent should be invalidated because the combination of two features of the invention is obvious), despite many years of legal practice well settled to the contrary by the U.S. Patent Office and the federal courts, one can no longer expect to obtain a U.S. patent for an invention that is "merely a combination of old elements" even if the Patent Office cannot show after substantive examination of the patent application that there is no teaching, suggestion or motivation in the prior art to make such inventive combination of elements.
 

4.  Increased damages are now extremely difficult to sanction against willful infringers.
 
In the recent In re Seagate Technology, LLC case (which reduced the likelihood of finding willful infringers by easing alleged infringers' affirmative duty to exercise due care in determining whether they were infringing once they had notice of a patent owner's rights), infringers who receive prior written notice to warn them against their continued willful trespass of one's patent rights are no longer held liable for paying multiple damages, unless the patent owner can meet the difficult standard of showing clear and convincing evidence that the infringer exhibited "objective recklessness."
 
5.  The situation is only getting worse for patent proponents.
 
The U.S. Patent Office is now seeking to dramatically limit the ability of patent applicants to continue to prosecute related patent applications via continuation application practice, and to substantially limit the number of patent claims that patent applicants could previously rightfully include together in a single patent application.   Furthermore, Congress is working hard to reform the U.S. patent laws to significantly reduce the reasonable royalties that a patent owner may recover as minimum remedies from guilty trespassers.
 
All the above recent changes to U.S. patent law have undermined patent owners' ability to derive value from their patents, severely weakening a system that previously encouraged inventors to innovate and publicly disclose their inventions. Without adequate reform returning rights to patent owners, the practice of applying for U.S. patents may soon no longer be worthwhile.

Submit an idea for an Expert Comment article. 



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .